PCVX: Vaxcyte Quarterly EPS earnings growth

The quarterly EPS trajectory demonstrates management efficiency, with the metric currently standing at -27.70. Operating profitability is supported by the diversification of component supplies and rigorous logistics. Stability in North American research offsets geopolitical risks. High physician confidence confirms the status of Vaxcyte, Inc. (PCVX) as a creator of breakthrough pneumococcal vaccines that are transforming global medical standards.

Vaxcyte Inc (PCVX) - Year-over-year net earnings per share growth for the last 12 months from 07/04/2022 to 11/14/2026

Summary analytical data breakdowns for SutroVax (PCVX)

- share price and expert price forecast:

Stock Price Vaxcyte|PCVX - Forecast Levels Chart

- market capitalization information:

Market Capitalization Vaxcyte Corp|PCVX - Total Enterprise Value

- balance sheet net asset value indicators:

Book Value per Share Vaxcyte|PCVX - Company Net Assets|Market Cap to Net Assets Ratio vaxcyte.com|PCVX - Aggregate Business Assets

- company liabilities and liquidity data:

- earnings and valuation multiples indicators:

PCVX - Company Net Income|Projected Future Earnings Vaxcyte, Inc.|PCVX - P/E Multiple|Projected Price to Earnings Vaxcyte Corp|PCVX - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Vaxcyte Corp|PCVX - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Vaxcyte|PCVX - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months vaxcyte.com|PCVX - Net earnings per one share growth for the current year|Earnings growth forecast for next year Vaxcyte, Inc.

- revenue and sales proceeds data:

PCVX - Company Total Revenue|Company Future Sales Volume Vaxcyte|PCVX - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Vaxcyte Corp

Comprehensive company analysis:Vaxcyte, Inc.

For Vaxcyte, Inc. (PCVX), which is developing the XpressCF closed-loop protein synthesis, this indicator serves as a measure of R&D monetization efficiency. The metric is calculated as the percentage change in net earnings per share compared to the same period last year. By analyzing the quarterly EPS growth history, an investor assesses the speed of business scaling. Sharp fluctuations in the curve signal volatility in vaccine development costs, while a stable trend confirms the sustainability of the company's technological advantage.

Key competitors